Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Adult and Adolescent Vaccines Market to 2017: Introduction | 11 | 2 |
| Overview | 11 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Market Overview | 13 | 2 |
| Vaccine Preventable Diseases | 13 | 1 |
| Vaccine Manufacturing Process | 14 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market | 15 | 14 |
| Market Forecasts | 15 | 2 |
| Market Share by Diseases Sector | 17 | 1 |
| Market Share by Geography | 18 | 1 |
| Average Cost of Vaccination per Child | 19 | 1 |
| Target Population | 19 | 3 |
| Immunization Coverage | 22 | 2 |
| Unmet Needs | 24 | 1 |
| Market Trends | 25 | 1 |
| Immunization Programs | 25 | 1 |
| Public Private Partnerships | 25 | 1 |
| Production Capacity | 26 | 1 |
| Reimbursements | 26 | 1 |
| Drivers | 26 | 1 |
| Growth will be Driven by Vaccines Targeting New Diseases | 27 | 1 |
| The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market | 27 | 1 |
| Pediatric Combination Vaccines will Continue to Drive Growth | 27 | 1 |
| Availability of Vaccine Technologies That Help Increase Efficacy and Safety will Drive Innovation and Growth | 27 | 1 |
| Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future | 27 | 1 |
| Barriers | 28 | 1 |
| Limitations in Production Capacity Delay the Realization of Potential | 28 | 1 |
| High Initial Capital Investments and Technical Expertise Act as Entry Barriers | 28 | 1 |
| Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance | 28 | 1 |
| Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market | 29 | 7 |
| Market Overview | 29 | 1 |
| Market Forecasts | 29 | 2 |
| Cost of Vaccination per Child in the US | 31 | 1 |
| Immunization Schedule | 32 | 1 |
| Regulatory Framework | 33 | 1 |
| Vaccine Procurement | 34 | 1 |
| Vaccine Stockpiling | 35 | 1 |
| Adult and Adolescent Vaccines Market to 2017: European Vaccines Market | 36 | 12 |
| Market Overview | 36 | 1 |
| Market Forecasts | 36 | 2 |
| Average Cost of Vaccination per Child | 38 | 1 |
| Vaccine Stockpiling | 38 | 1 |
| The UK | 39 | 1 |
| Immunization Schedule | 39 | 1 |
| Regulatory Framework | 39 | 1 |
| Vaccine Procurement | 39 | 1 |
| France | 40 | 1 |
| Immunization Schedule | 40 | 1 |
| Regulatory Framework | 41 | 1 |
| Vaccine Procurement | 41 | 1 |
| Germany | 42 | 1 |
| Immunization Schedule | 42 | 1 |
| Regulatory Framework | 43 | 1 |
| Vaccine Procurement | 44 | 1 |
| Italy | 44 | 1 |
| Immunization Schedule | 44 | 1 |
| Regulatory Framework | 44 | 1 |
| Vaccine Procurement | 45 | 1 |
| Spain | 45 | 1 |
| Immunization Schedule | 45 | 1 |
| Regulatory Framework | 46 | 1 |
| Vaccine Procurement | 47 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Rest of the World Vaccines Market | 48 | 3 |
| Market Overview | 48 | 1 |
| Market Forecasts | 48 | 1 |
| Average Cost of Vaccination per Child | 49 | 1 |
| Immunization Schedule | 49 | 1 |
| Regulatory Framework | 49 | 1 |
| Vaccine Procurement | 49 | 1 |
| Vaccine Stockpiling | 50 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market | 51 | 8 |
| Market Overview | 51 | 1 |
| Market Forecasts | 51 | 1 |
| Average Cost of Vaccination | 52 | 1 |
| Target Population | 53 | 1 |
| Immunization Coverage | 54 | 1 |
| Product Analysis | 54 | 1 |
| Prevnar 7 | 54 | 1 |
| Overview | 54 | 1 |
| Efficacy | 54 | 1 |
| Annual Cost of Therapy | 54 | 1 |
| Prevnar 13 (pneumococcal 13-valent conjugate vaccine) | 54 | 1 |
| Overview | 54 | 1 |
| Efficacy | 55 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Pneumovax 23 | 55 | 1 |
| Overview | 55 | 1 |
| Efficacy | 55 | 1 |
| Annual Cost of Therapy | 56 | 1 |
| Synflorix | 56 | 1 |
| Overview | 56 | 1 |
| Efficacy | 56 | 1 |
| Annual Cost of Therapy | 56 | 1 |
| Vaccine Pipeline Analysis | 57 | 1 |
| Phase lll | 57 | 1 |
| Phase ll | 58 | 1 |
| Phase l | 58 | 1 |
| Preclinical/Discovery | 58 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus Vaccines Market | 59 | 8 |
| Market Overview | 59 | 1 |
| Market Forecasts | 59 | 1 |
| Average Cost of Vaccination | 60 | 1 |
| Target Population | 61 | 1 |
| Immunization Coverage | 62 | 1 |
| Product Analysis | 62 | 1 |
| Gardasil | 62 | 1 |
| Overview | 62 | 1 |
| Indications | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| Dosage | 63 | 1 |
| Cervarix | 63 | 1 |
| Overview | 63 | 1 |
| Indications | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| Dosage | 63 | 1 |
| Vaccine Pipeline Analysis | 63 | 1 |
| Phase lll | 63 | 1 |
| Phase ll | 64 | 1 |
| Phase l | 65 | 1 |
| Preclinical/Discovery | 66 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market | 67 | 12 |
| Market Overview | 67 | 4 |
| Average Cost of Vaccination | 71 | 1 |
| Target Population | 72 | 1 |
| Immunization Coverage | 73 | 1 |
| Product Analysis | 73 | 1 |
| Fluzone | 73 | 1 |
| Overview | 73 | 1 |
| Indications | 73 | 1 |
| Dosage | 73 | 1 |
| Fluarix | 73 | 1 |
| Overview | 73 | 1 |
| Indications | 73 | 1 |
| Dosage | 73 | 1 |
| Vaccine Pipeline Analysis | 74 | 1 |
| Regulatory Filed Products | 74 | 1 |
| Phase lll | 74 | 1 |
| Phase ll | 75 | 1 |
| Phase l | 76 | 1 |
| Preclinical/Discovery | 77 | 2 |
| Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market | 79 | 7 |
| Market Overview | 79 | 1 |
| Market Forecasts | 79 | 1 |
| Average Cost of Vaccination | 80 | 1 |
| Target Population | 81 | 1 |
| Product Analysis | 82 | 1 |
| Twinrix | 82 | 1 |
| Overview | 82 | 1 |
| Efficacy | 82 | 1 |
| Safety | 82 | 1 |
| Pricing | 82 | 1 |
| Clinical Study Details | 82 | 1 |
| Havrix | 83 | 1 |
| Overview | 83 | 1 |
| Efficacy | 83 | 1 |
| Annual Cost of Therapy | 83 | 1 |
| Vaqta | 83 | 1 |
| Overview | 83 | 1 |
| Efficacy | 83 | 1 |
| Ambirix | 84 | 1 |
| Overview | 84 | 1 |
| Efficacy | 84 | 1 |
| Annual cost of therapy | 84 | 1 |
| Avaxim | 84 | 1 |
| Overview | 84 | 1 |
| Efficacy | 84 | 1 |
| Vaccine Pipeline Analysis | 85 | 1 |
| NDA Filed Molecules | 85 | 1 |
| Phase lll | 85 | 1 |
| Preclinical/Discovery | 85 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market | 86 | 9 |
| Market Overview | 86 | 1 |
| Market Forecasts | 87 | 1 |
| Average Cost of Vaccination | 88 | 1 |
| Target Population | 89 | 1 |
| Product Analysis | 90 | 1 |
| Recombivax HB | 90 | 1 |
| Overview | 90 | 1 |
| Efficacy | 90 | 1 |
| Pricing | 90 | 1 |
| Engerix-B | 90 | 1 |
| Overview | 90 | 1 |
| Efficacy | 90 | 1 |
| Pricing | 90 | 1 |
| Twinrix | 91 | 1 |
| Overview | 91 | 1 |
| Efficacy | 91 | 1 |
| Pricing | 91 | 1 |
| Comvax | 91 | 1 |
| Overview | 91 | 1 |
| Efficacy | 91 | 1 |
| Pricing | 91 | 1 |
| Vaccine Pipeline Analysis | 91 | 1 |
| Regulatory Filed Products | 91 | 1 |
| Phase lll | 92 | 1 |
| Phase ll | 93 | 1 |
| Phase l | 93 | 1 |
| Preclinical/Discovery | 94 | 1 |
| Adult and Adolescent Vaccines Market to 2017: Competitive Landscape | 95 | 3 |
| Overview | 95 | 1 |
| Market Share Analysis | 96 | 2 |
| Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations | 98 | 15 |
| Mergers &Acquisitions | 98 | 1 |
| Overview | 98 | 1 |
| Top Deals in M&A | 98 | 1 |
| M&A by Indication | 99 | 1 |
| M&A by Year | 100 | 1 |
| M&A by Geography | 101 | 1 |
| M&A by Value | 102 | 1 |
| Licensing Agreements | 103 | 1 |
| Overview | 103 | 1 |
| Top Licensing Deals | 103 | 1 |
| Licensing Deals by Indication | 104 | 1 |
| Licensing Deals by Year | 105 | 1 |
| Licensing Deals by Geography | 106 | 1 |
| Licensing Deals by Value | 107 | 1 |
| Co-Development Deals | 108 | 1 |
| Overview | 108 | 1 |
| Top Co-Development Deals | 108 | 1 |
| Co-Development Deals by Indication | 109 | 1 |
| Co-Development Deals by Year | 110 | 1 |
| Co-Development Deals by Geography | 111 | 1 |
| Co-Development Deals by Value | 112 | 1 |
| Appendix | 113 | 6 |
| Market Definitions | 113 | 1 |
| Abbreviations | 113 | 1 |
| Research Methodology | 114 | 1 |
| Global Vaccines Market | 114 | 2 |
| Coverage | 114 | 1 |
| Sources of Coverage | 115 | 1 |
| Methodology | 115 | 1 |
| Geographical Landscape | 115 | 1 |
| Coverage | 115 | 1 |
| Sources of Coverage | 115 | 1 |
| Methodology | 115 | 1 |
| Market Characterization | 116 | 1 |
| Coverage | 116 | 1 |
| Sources of Coverage | 116 | 1 |
| Methodology | 116 | 1 |
| Competitive Landscape | 116 | 2 |
| Coverage | 116 | 1 |
| Sources of Coverage | 116 | 1 |
| Methodology | 117 | 1 |
| Pipeline Analysis | 117 | 1 |
| Coverage | 117 | 1 |
| Sources of Coverage | 117 | 1 |
| Methodology | 117 | 1 |